{"product_id":"dhr-business-model-canvas","title":"Danaher Corporation (DHR): Business Model Canvas [June-2026 Updated]","description":"\u003cp\u003eThis ready-made Danaher Corporation business model canvas gives you a practical, research-based view of how the company creates value through lean execution, AI-enabled diagnostics and automation, and high-recurring consumables. You'll quickly see the key customer segments, direct sales and installed-base channels, recurring revenue from bioprocessing consumables and diagnostics assays, major cost drivers such as manufacturing, R\u0026amp;D, integration, and restructuring, plus the strategic resources and partnerships that shape performance, including Automata, AstraZeneca, biopharma customers, and Masimo shareholders.\u003c\/p\u003e\u003ch2\u003eDanaher Corporation - Canvas Business Model: Key Partnerships\u003c\/h2\u003e\n\u003cp\u003eDanaher Corporation's key partnerships sit in automation, diagnostics, and acquisition execution, with the clearest public numbers being \u003cstrong\u003e$23.9 billion\u003c\/strong\u003e of 2023 revenue for Danaher Corporation, \u003cstrong\u003e$45.8 billion\u003c\/strong\u003e of 2023 revenue for AstraZeneca, \u003cstrong\u003e$11.4 billion\u003c\/strong\u003e of 2023 R\u0026amp;D for AstraZeneca, and the \u003cstrong\u003e$5.7 billion\u003c\/strong\u003e Abcam acquisition at \u003cstrong\u003e$24.00\u003c\/strong\u003e per share.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartnership theme\u003c\/td\u003e\n\u003ctd\u003eReal-life numeric anchor\u003c\/td\u003e\n\u003ctd\u003eCanvas role\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAutomata\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$23.9 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDanaher Corporation 2023 revenue supports automation partnerships\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAstraZeneca\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$45.8 billion\u003c\/strong\u003e; \u003cstrong\u003e$11.4 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e2023 revenue and R\u0026amp;D show customer scale for diagnostics and research tools\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiopharma customers\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$24.00\u003c\/strong\u003e per share; \u003cstrong\u003e$5.7 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAbcam acquisition shows acquisition-level capability building for life sciences customers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShareholder approval\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$24.00\u003c\/strong\u003e per share; \u003cstrong\u003e$5.7 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eShows how Danaher Corporation closes control transactions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eAutomata\u003c\/strong\u003e fits Danaher Corporation's automation layer because Danaher Corporation's \u003cstrong\u003e$23.9 billion\u003c\/strong\u003e 2023 revenue base gives it the scale to fund lab workflow automation and AI-ready integration. No public transaction value has been disclosed for this relationship.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAstraZeneca\u003c\/strong\u003e is the clearest large-customer example. AstraZeneca reported \u003cstrong\u003e$45.8 billion\u003c\/strong\u003e of 2023 revenue and spent \u003cstrong\u003e$11.4 billion\u003c\/strong\u003e on R\u0026amp;D, which makes it a high-value buyer for diagnostics and research tools tied to drug development.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eBiopharma customers\u003c\/strong\u003e matter most in reshoring projects because Danaher Corporation can sell the same production and quality-control stack across multiple sites. The strongest public deal number in this logic is Danaher Corporation's Abcam purchase at \u003cstrong\u003e$24.00\u003c\/strong\u003e per share for \u003cstrong\u003e$5.7 billion\u003c\/strong\u003e, showing the price Danaher Corporation pays for capability that serves drug-development customers.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eMasimo shareholders\u003c\/strong\u003e do not map to a public Danaher Corporation transaction record in the disclosed numbers. The relevant shareholder-approval precedent in Danaher Corporation's own record is the \u003cstrong\u003e$24.00\u003c\/strong\u003e per share, \u003cstrong\u003e$5.7 billion\u003c\/strong\u003e Abcam deal.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$23.9 billion\u003c\/strong\u003e Danaher Corporation 2023 revenue supports external automation partnerships.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$45.8 billion\u003c\/strong\u003e AstraZeneca 2023 revenue makes it a meaningful diagnostics customer.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$11.4 billion\u003c\/strong\u003e AstraZeneca 2023 R\u0026amp;D spend supports demand for research tools.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$24.00\u003c\/strong\u003e per share and \u003cstrong\u003e$5.7 billion\u003c\/strong\u003e in the Abcam deal show acquisition-level partnership economics.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eDanaher Corporation - Canvas Business Model: Key Activities\u003c\/h2\u003e\n\u003cp\u003eDanaher Corporation's key activities are built around \u003cstrong\u003e3\u003c\/strong\u003e reporting segments and \u003cstrong\u003e$23.9 billion\u003c\/strong\u003e of 2024 revenue, with Danaher Business System at the center of execution.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eLean execution via Danaher Business System\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDanaher Business System is the operating core behind the company's daily management, problem solving, kaizen, standard work, and value-stream improvement. This matters because Danaher runs large regulated businesses, so small gains in yield, cycle time, and quality can affect margin and customer retention across a \u003cstrong\u003e$23.9 billion\u003c\/strong\u003e revenue base. The system also gives Danaher a repeatable way to integrate new businesses into the same operating discipline. That is why lean execution is not a side process; it is a main value-creation activity.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eBioprocessing and diagnostics manufacturing\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDanaher's manufacturing work is concentrated in bioprocessing, diagnostics, and life sciences instruments. These operations depend on validated production, traceability, supplier control, calibration, sterility, and lot release. In bioprocessing, manufacturing quality affects the supply of tools and consumables used in biologics production. In diagnostics, manufacturing quality affects test reliability, install base performance, and recurring reagent demand. For Danaher, manufacturing is a revenue activity because customers in pharma and healthcare pay for consistency, compliance, and supply assurance, not only for hardware.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAI and digital product development\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDanaher's digital work supports connected instruments, workflow software, data analysis, software validation, and cybersecurity. In regulated products, software is part of the product, so development has to cover both performance and compliance. That means digital work affects product launch timing, serviceability, and customer adoption. For academic work, this is important because Danaher's key activities now combine physical manufacturing with software engineering and data handling inside the same operating model.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eM\u0026amp;A integration and portfolio optimization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePortfolio work is a core activity because Danaher uses acquisitions and divestitures to shift capital toward higher-growth platforms. Danaher separated Veralto on \u003cstrong\u003eSeptember 30, 2023\u003c\/strong\u003e. Danaher also agreed to acquire Abcam for \u003cstrong\u003e$24.00 per share\u003c\/strong\u003e in cash, with an equity value of about \u003cstrong\u003e$5.7 billion\u003c\/strong\u003e. Those numbers show how Danaher uses M\u0026amp;A to reshape the portfolio while keeping DBS, quality systems, and manufacturing integration in place. Integration is part of the business model because a deal only matters if Danaher can absorb the business into its operating system.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRegulatory submissions and product clearances\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDanaher's commercial launch activity depends on regulatory submissions and clearances such as FDA \u003cstrong\u003e510(k)\u003c\/strong\u003e, PMA, de novo, Emergency Use Authorization, and European CE marking under \u003cstrong\u003eIVDR 2017\/746\u003c\/strong\u003e and \u003cstrong\u003eMDR 2017\/745\u003c\/strong\u003e. These pathways control when a product can enter the market, how much evidence Danaher must file, and how long revenue may be delayed. In diagnostics, a delayed clearance can affect instrument placement and reagent pull-through. In bioprocessing, regulatory documentation still matters because customers need validated, traceable supply chains for therapeutic production.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eKey activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eReal-life number or amount\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eBusiness effect\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating scale\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e reporting segments\u003c\/td\u003e\n\u003ctd\u003eStandardized execution across Biotechnology, Diagnostics, and Life Sciences\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue base\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$23.9 billion\u003c\/strong\u003e in 2024\u003c\/td\u003e\n\u003ctd\u003eSmall efficiency gains have a large dollar impact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePortfolio reset\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSeptember 30, 2023\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFocused the company on life sciences and diagnostics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisition integration\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$24.00\u003c\/strong\u003e per share; about \u003cstrong\u003e$5.7 billion\u003c\/strong\u003e equity value\u003c\/td\u003e\n\u003ctd\u003eExpands biopharma tools and adds integration work\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory access\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e510(k)\u003c\/strong\u003e, \u003cstrong\u003eIVDR 2017\/746\u003c\/strong\u003e, \u003cstrong\u003eMDR 2017\/745\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eControls market entry timing and compliance burden\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e segments require one operating system, not \u003cstrong\u003e3\u003c\/strong\u003e separate ones\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$23.9 billion\u003c\/strong\u003e of 2024 revenue makes lean execution financially material\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$24.00\u003c\/strong\u003e per share and about \u003cstrong\u003e$5.7 billion\u003c\/strong\u003e show the size of Danaher's acquisition moves\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSeptember 30, 2023\u003c\/strong\u003e marks the portfolio shift that narrowed the business mix\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e510(k)\u003c\/strong\u003e, \u003cstrong\u003eIVDR 2017\/746\u003c\/strong\u003e, and \u003cstrong\u003eMDR 2017\/745\u003c\/strong\u003e show how regulation shapes launches\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eLean execution via Danaher Business System\u003c\/strong\u003e turns operational discipline into repeatable margin control, quality control, and integration control.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eBioprocessing and diagnostics manufacturing\u003c\/strong\u003e turns regulated production into a source of customer trust and recurring demand.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAI and digital product development\u003c\/strong\u003e turns software, data, and validation into part of the product itself.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eM\u0026amp;A integration and portfolio optimization\u003c\/strong\u003e turn deals and divestitures into portfolio reshaping.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRegulatory submissions and product clearances\u003c\/strong\u003e turn compliance timing into revenue timing.\u003c\/p\u003e\n\u003ch2\u003eDanaher Corporation - Canvas Business Model: Key Resources\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e1984\u003c\/strong\u003e, \u003cstrong\u003e3\u003c\/strong\u003e reportable segments, \u003cstrong\u003e63,000\u003c\/strong\u003e associates, \u003cstrong\u003e$23.9B\u003c\/strong\u003e 2024 net sales, and \u003cstrong\u003e$6.1B\u003c\/strong\u003e 2024 operating cash flow.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eKey resource\u003c\/th\u003e\n\u003cth\u003eNumber\u003c\/th\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDanaher Business System\u003c\/td\u003e\n\u003ctd\u003e1984\u003c\/td\u003e\n\u003ctd\u003eformation year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReportable segments\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003ctd\u003eBiotechnology, Life Sciences, Diagnostics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAssociates\u003c\/td\u003e\n\u003ctd\u003e63,000\u003c\/td\u003e\n\u003ctd\u003eworldwide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 net sales\u003c\/td\u003e\n\u003ctd\u003e$23.9B\u003c\/td\u003e\n\u003ctd\u003erevenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 operating cash flow\u003c\/td\u003e\n\u003ctd\u003e$6.1B\u003c\/td\u003e\n\u003ctd\u003ecash from operations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating cash flow margin\u003c\/td\u003e\n\u003ctd\u003e25.5%\u003c\/td\u003e\n\u003ctd\u003e$6.1B \/ $23.9B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales per associate\u003c\/td\u003e\n\u003ctd\u003e$379,000\u003c\/td\u003e\n\u003ctd\u003e$23.9B \/ 63,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eDanaher Business System\u003c\/strong\u003e: \u003cstrong\u003e1984\u003c\/strong\u003e; \u003cstrong\u003e3\u003c\/strong\u003e reportable segments.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eGlobal life sciences and diagnostics platforms\u003c\/strong\u003e: \u003cstrong\u003e3\u003c\/strong\u003e reportable segments; \u003cstrong\u003e$23.9B\u003c\/strong\u003e 2024 net sales.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eStrong recurring consumables base\u003c\/strong\u003e: \u003cstrong\u003e$21.4B\u003c\/strong\u003e, \u003cstrong\u003e$9.6B\u003c\/strong\u003e, \u003cstrong\u003e$5.7B\u003c\/strong\u003e; combined \u003cstrong\u003e$36.7B\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003ePlatform deal\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003eYear\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGE Biopharma\u003c\/td\u003e\n\u003ctd\u003e$21.4B\u003c\/td\u003e\n\u003ctd\u003e2020\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAldevron\u003c\/td\u003e\n\u003ctd\u003e$9.6B\u003c\/td\u003e\n\u003ctd\u003e2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAbcam\u003c\/td\u003e\n\u003ctd\u003e$5.7B\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eAI leadership and digital talent\u003c\/strong\u003e: \u003cstrong\u003e63,000\u003c\/strong\u003e associates; \u003cstrong\u003e$379,000\u003c\/strong\u003e sales per associate.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCash flow and investment capacity\u003c\/strong\u003e: \u003cstrong\u003e$6.1B\u003c\/strong\u003e operating cash flow; \u003cstrong\u003e25.5%\u003c\/strong\u003e operating cash flow margin; \u003cstrong\u003e$36.7B\u003c\/strong\u003e combined acquisition value.\u003c\/p\u003e\u003ch2\u003eDanaher Corporation - Canvas Business Model: Value Propositions\u003c\/h2\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue proposition support\u003c\/td\u003e\n\u003ctd\u003eReal-life metric\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003eDate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScale\u003c\/td\u003e\n\u003ctd\u003eNet sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$23.859 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStructure\u003c\/td\u003e\n\u003ctd\u003eOperating segments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorkforce\u003c\/td\u003e\n\u003ctd\u003eEmployees\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e63,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eyear-end 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePortfolio expansion\u003c\/td\u003e\n\u003ctd\u003eAbcam acquisition\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.7 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePortfolio change\u003c\/td\u003e\n\u003ctd\u003eVeralto spin-off close\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSeptember 30, 2023\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eHigh-recurring consumables and assays\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$5.7 billion\u003c\/strong\u003e Abcam acquisition in 2023.\u003c\/li\u003e\n\u003cli\u003eAbcam antibodies and reagents.\u003c\/li\u003e\n\u003cli\u003eIntegrated DNA Technologies oligonucleotides.\u003c\/li\u003e\n\u003cli\u003eCepheid test cartridges.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eIntegrated bioprocessing and diagnostics solutions\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e operating segments: Biotechnology, Life Sciences, Diagnostics.\u003c\/li\u003e\n\u003cli\u003eCytiva and Pall in Biotechnology.\u003c\/li\u003e\n\u003cli\u003eCepheid and Leica Biosystems in Diagnostics.\u003c\/li\u003e\n\u003cli\u003eBeckman Coulter Life Sciences, SCIEX, and Molecular Devices in Life Sciences.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eFaster manufacturing and workflow efficiency\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e63,000\u003c\/strong\u003e employees at year-end 2023.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$23.859 billion\u003c\/strong\u003e net sales in 2023.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSeptember 30, 2023\u003c\/strong\u003e Veralto spin-off close.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eAI-enabled drug discovery and analytics\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSCIEX.\u003c\/li\u003e\n\u003cli\u003eMolecular Devices.\u003c\/li\u003e\n\u003cli\u003eBeckman Coulter Life Sciences.\u003c\/li\u003e\n\u003cli\u003eAbcam.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eStrong profitability and reliability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$23.859 billion\u003c\/strong\u003e net sales in 2023.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e operating segments.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e63,000\u003c\/strong\u003e employees at year-end 2023.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eDanaher Corporation - Canvas Business Model: Customer Relationships\u003c\/h2\u003e\n\u003cp\u003eDanaher Corporation's customer relationships are built on long-term enterprise accounts, repeat consumable purchases, and technical support that keeps regulated workflows in place. The model works best where an initial instrument or platform sale leads to years of follow-on orders for reagents, assays, service, and upgrades.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eLong-term enterprise customer relationships\u003c\/strong\u003e matter because Danaher sells into buying processes that are slow, technical, and regulated. In Biotechnology, Life Sciences, and Diagnostics, customers usually validate a platform before they adopt it, then stay with it because changing systems is expensive and risky. After the \u003cstrong\u003eSeptember 30, 2023\u003c\/strong\u003e spin-off of Veralto, Danaher remained focused on \u003cstrong\u003e3\u003c\/strong\u003e core segments, which sharpened the company's account coverage around these specialized workflows.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eCustomer relationship layer\u003c\/th\u003e\n\u003cth\u003eCustomer type\u003c\/th\u003e\n\u003cth\u003eReal-life numeric anchor\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLong-term enterprise relationships\u003c\/td\u003e\n\u003ctd\u003eBiotechnology, Life Sciences, and Diagnostics customers\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e core segments after \u003cstrong\u003eSeptember 30, 2023\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSupports multi-year account control and deeper switching costs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring consumables-driven engagement\u003c\/td\u003e\n\u003ctd\u003eInstrument users that reorder reagents, assays, and single-use products\u003c\/td\u003e\n\u003ctd\u003eAbcam acquisition completed on \u003cstrong\u003eDecember 6, 2023\u003c\/strong\u003e for approximately \u003cstrong\u003e$5.7 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eExpands repeat-purchase product depth around installed workflows\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategic collaboration with pharma customers\u003c\/td\u003e\n\u003ctd\u003eBiopharma and cell and gene therapy developers\u003c\/td\u003e\n\u003ctd\u003eAldevron acquisition completed in \u003cstrong\u003e2021\u003c\/strong\u003e for \u003cstrong\u003e$9.6 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eLinks Danaher to development, scale-up, and GMP-related supply needs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOngoing product and assay expansion\u003c\/td\u003e\n\u003ctd\u003eExisting research and diagnostic accounts\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eDecember 6, 2023\u003c\/strong\u003e and \u003cstrong\u003eSeptember 30, 2023\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eGives current customers more products to buy from the same group\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRecurring consumables-driven engagement\u003c\/strong\u003e is the clearest customer relationship loop in Danaher's model. Once a customer has installed and validated a system, the relationship does not end at the sale. It usually shifts into repeat orders for consumables, reagents, cartridges, filters, assay kits, and service parts. That matters because recurring purchases are tied to workflow continuity, not just one-time buying. The \u003cstrong\u003eDecember 6, 2023\u003c\/strong\u003e acquisition of Abcam for approximately \u003cstrong\u003e$5.7 billion\u003c\/strong\u003e strengthened this pattern by adding antibody and protein research products that fit repeat purchasing behavior.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eSeptember 30, 2023\u003c\/strong\u003e: Danaher completed the Veralto spin-off and moved to \u003cstrong\u003e3\u003c\/strong\u003e core segments.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDecember 6, 2023\u003c\/strong\u003e: Danaher completed the Abcam acquisition for approximately \u003cstrong\u003e$5.7 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2021\u003c\/strong\u003e: Danaher completed the Aldevron acquisition for \u003cstrong\u003e$9.6 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eTechnical support and application expertise\u003c\/strong\u003e are part of the customer relationship, not a side service. Danaher customers often need help with installation, validation, method transfer, training, and troubleshooting. In plain English, method transfer means moving a tested process from one lab or site to another without breaking performance. That matters in diagnostics and biomanufacturing because downtime or inconsistency can delay results, production, or regulatory work. When Danaher keeps customers running, it protects the installed base and strengthens the chance of future orders.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eStrategic collaboration with pharma customers\u003c\/strong\u003e is most important in biopharmaceutical development and manufacturing. These relationships are usually not limited to buying products off a shelf. They often involve process development, scale-up support, and supply continuity across multiple stages of a drug program. The \u003cstrong\u003e$9.6 billion\u003c\/strong\u003e Aldevron acquisition in \u003cstrong\u003e2021\u003c\/strong\u003e matters because it deepens Danaher's ties to customers working in advanced therapies and biologics, where supply reliability and technical coordination are central to the relationship.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOngoing product and assay expansion\u003c\/strong\u003e keeps existing customers inside Danaher's ecosystem for longer. The logic is simple: if the customer already trusts one product line, adding adjacent products makes it easier to buy more from the same supplier. The \u003cstrong\u003e$5.7 billion\u003c\/strong\u003e Abcam deal completed on \u003cstrong\u003eDecember 6, 2023\u003c\/strong\u003e is important here because it broadens the research reagent and assay catalog. For an academic case study, this is a strong example of how a company uses portfolio expansion to deepen customer retention without relying on price alone.\u003c\/p\u003e\u003ch2\u003eDanaher Corporation - Canvas Business Model: Channels\u003c\/h2\u003e\n\u003cp\u003eDanaher Corporation's channels are built around direct account selling, installed-base replenishment, instrument placements, co-development-linked deals, and large field-service networks. The company reported \u003cstrong\u003e$23.890B\u003c\/strong\u003e of 2023 revenue and had about \u003cstrong\u003e63,000\u003c\/strong\u003e employees.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eReal-life numbers\u003c\/th\u003e\n\u003cth\u003eChannel role\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales to biopharma and diagnostics buyers\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$23.890B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2023 revenue base supported by direct customer coverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstalled-base consumables replenishment\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e40,000+\u003c\/strong\u003e GeneXpert systems\u003c\/td\u003e\n\u003ctd\u003eRecurring cartridge, reagent, and service demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstrument and analyzer placements\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e reporting segments\u003c\/td\u003e\n\u003ctd\u003eBiotechnology, Life Sciences, Diagnostics placement mix\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategic partnerships and co-development\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$24.00\u003c\/strong\u003e per share; \u003cstrong\u003e$5.7B\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAbcam transaction value and cash offer price\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal commercial and service teams\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e63,000\u003c\/strong\u003e employees\u003c\/td\u003e\n\u003ctd\u003eSales, installation, validation, and field service coverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eDirect sales to biopharma and diagnostics buyers\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDanaher Corporation sells directly into biopharma manufacturing, clinical diagnostics, reference labs, hospitals, and research labs. Its \u003cstrong\u003e3\u003c\/strong\u003e reporting segments, Biotechnology, Life Sciences, and Diagnostics, align with those buyer groups and support account-based selling rather than retail distribution.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eInstalled-base consumables replenishment\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe installed base is a core channel asset. Cepheid reported more than \u003cstrong\u003e40,000\u003c\/strong\u003e GeneXpert systems installed globally, and each installed system creates repeat demand for cartridges, reagents, and service parts. This channel structure ties future revenue to the size of the instrument base already placed.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e40,000+\u003c\/strong\u003e installed GeneXpert systems\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e instrument base can generate repeated consumable orders\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e segments support different replenishment cycles\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eInstrument and analyzer placements\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDanaher uses placements to put instruments, analyzers, and systems into customer sites first, then earns follow-on revenue from consumables and service. The company's 2023 revenue of \u003cstrong\u003e$23.890B\u003c\/strong\u003e reflects this mix across diagnostics and bioprocessing workflows.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003ePlacement channel item\u003c\/th\u003e\n\u003cth\u003eNumber\u003c\/th\u003e\n\u003cth\u003eCommercial effect\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2023 revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$23.890B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eScale for installed-base monetization\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReporting segments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMultiple placement pathways\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstalled GeneXpert systems\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e40,000+\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRecurring consumables pull-through\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eStrategic partnerships and co-development\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDanaher's 2023 acquisition of Abcam was priced at \u003cstrong\u003e$24.00\u003c\/strong\u003e per share in cash, with an equity value of about \u003cstrong\u003e$5.7B\u003c\/strong\u003e. That transaction expanded access to research reagents and antibody-related workflows, which are often used in co-development and application-specific selling.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eGlobal commercial and service teams\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDanaher had about \u003cstrong\u003e63,000\u003c\/strong\u003e employees, giving it a large commercial and service footprint for installation, calibration, validation, and troubleshooting. That scale matters in diagnostics and bioprocessing because many customer sites need local field support after placement.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e63,000\u003c\/strong\u003e employees\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$23.890B\u003c\/strong\u003e 2023 revenue\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e reporting segments\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e40,000+\u003c\/strong\u003e installed GeneXpert systems\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$5.7B\u003c\/strong\u003e Abcam equity value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eDanaher Corporation - Canvas Business Model: Customer Segments\u003c\/h2\u003e\n\u003cp\u003eDanaher Corporation's customer base sits inside \u003cstrong\u003e3\u003c\/strong\u003e reporting segments: Biotechnology, Life Sciences, and Diagnostics. The buyer mix is concentrated in \u003cstrong\u003e5\u003c\/strong\u003e B2B groups, with demand tied to \u003cstrong\u003e50\u003c\/strong\u003e FDA novel drug approvals in 2024, \u003cstrong\u003e55\u003c\/strong\u003e in 2023, about \u003cstrong\u003e14\u003c\/strong\u003e billion U.S. clinical lab tests a year, \u003cstrong\u003e$108.8 billion\u003c\/strong\u003e in U.S. higher-education R\u0026amp;D spending in FY2023, and about \u003cstrong\u003e$2.3 trillion\u003c\/strong\u003e in U.S. manufacturing value added in 2023.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eCustomer segment\u003c\/th\u003e\n\u003cth\u003eReal-life numeric anchor\u003c\/th\u003e\n\u003cth\u003ePrimary buying needs\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiopharmaceutical manufacturers\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e50\u003c\/strong\u003e FDA novel drug approvals in 2024; \u003cstrong\u003e55\u003c\/strong\u003e in 2023\u003c\/td\u003e\n\u003ctd\u003eBioprocessing, purification, filtration, single-use systems\u003c\/td\u003e\n\u003ctd\u003eScale-up and commercial launch create repeat demand for consumables, systems, and validation support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical diagnostics laboratories\u003c\/td\u003e\n\u003ctd\u003eAbout \u003cstrong\u003e14\u003c\/strong\u003e billion U.S. lab tests annually\u003c\/td\u003e\n\u003ctd\u003eAnalyzers, reagents, controls, service\u003c\/td\u003e\n\u003ctd\u003eHigh test volume supports recurring purchases and uptime-sensitive service contracts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic research institutions\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$108.8 billion\u003c\/strong\u003e in U.S. higher-education R\u0026amp;D spending in FY2023\u003c\/td\u003e\n\u003ctd\u003eInstruments, consumables, maintenance, service\u003c\/td\u003e\n\u003ctd\u003eGrant-driven budgets support cyclical purchasing and long equipment replacement cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma R\u0026amp;D and drug discovery teams\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e55\u003c\/strong\u003e FDA novel drug approvals in 2023; \u003cstrong\u003e50\u003c\/strong\u003e in 2024\u003c\/td\u003e\n\u003ctd\u003eScreening tools, sample prep, analytical systems\u003c\/td\u003e\n\u003ctd\u003eEarly-stage pipeline spending comes before commercial revenue, so workflow productivity matters\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegional manufacturing customers\u003c\/td\u003e\n\u003ctd\u003eAbout \u003cstrong\u003e$2.3 trillion\u003c\/strong\u003e in U.S. manufacturing value added in 2023\u003c\/td\u003e\n\u003ctd\u003eQuality control, process measurement, service, localized support\u003c\/td\u003e\n\u003ctd\u003eRegional plants need qualification, compliance, and supply continuity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiopharmaceutical manufacturers\u003c\/strong\u003e: \u003cstrong\u003e50\u003c\/strong\u003e FDA novel drug approvals in 2024 and \u003cstrong\u003e55\u003c\/strong\u003e in 2023 point to a pipeline that still requires scale-up equipment, process validation, and repeat production purchases. This segment matters because every approved molecule can turn into years of recurring process demand.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eClinical diagnostics laboratories\u003c\/strong\u003e: About \u003cstrong\u003e14\u003c\/strong\u003e billion U.S. lab tests each year creates a large installed base for analyzers, reagents, calibrators, and service. This segment matters because test volume drives recurring consumable revenue and makes uptime critical.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAcademic research institutions\u003c\/strong\u003e: \u003cstrong\u003e$108.8 billion\u003c\/strong\u003e in U.S. higher-education R\u0026amp;D spending in FY2023 supports instrument purchases, lab consumables, and service contracts. This segment matters because funding flows through grants and budgets, so demand can be lumpy but broad.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePharma R\u0026amp;D and drug discovery teams\u003c\/strong\u003e: The move from discovery to approval is visible in the FDA's \u003cstrong\u003e55\u003c\/strong\u003e approvals in 2023 and \u003cstrong\u003e50\u003c\/strong\u003e in 2024. This segment matters because it buys upstream tools first, before scale-up and manufacturing spending start.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegional manufacturing customers\u003c\/strong\u003e: About \u003cstrong\u003e$2.3 trillion\u003c\/strong\u003e in U.S. manufacturing value added in 2023 shows the scale of industrial customers that need quality, traceability, and local service. This segment matters because local plants often buy on qualification, response time, and supply continuity.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eDanaher Corporation - Canvas Business Model: Cost Structure\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e2024 net sales:\u003c\/strong\u003e $23.9B. \u003cstrong\u003eCost of sales:\u003c\/strong\u003e $9.1B. \u003cstrong\u003eGross profit:\u003c\/strong\u003e $14.8B. \u003cstrong\u003eResearch and development expense:\u003c\/strong\u003e $1.6B. \u003cstrong\u003eSelling, general and administrative expenses:\u003c\/strong\u003e $4.8B. \u003cstrong\u003eRestructuring and other charges:\u003c\/strong\u003e $0.1B.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost structure item\u003c\/td\u003e\n\u003ctd\u003e2024 amount\u003c\/td\u003e\n\u003ctd\u003eCalculation or basis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing and supply chain\u003c\/td\u003e\n\u003ctd\u003e$9.1B\u003c\/td\u003e\n\u003ctd\u003eCost of sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross profit\u003c\/td\u003e\n\u003ctd\u003e$14.8B\u003c\/td\u003e\n\u003ctd\u003e$23.9B - $9.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D and AI development\u003c\/td\u003e\n\u003ctd\u003e$1.6B\u003c\/td\u003e\n\u003ctd\u003eResearch and development expense\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisition and integration\u003c\/td\u003e\n\u003ctd\u003e$0.1B\u003c\/td\u003e\n\u003ctd\u003eAcquisition-related transaction and integration costs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisition-related intangible amortization\u003c\/td\u003e\n\u003ctd\u003e$1.0B\u003c\/td\u003e\n\u003ctd\u003eAmortization of intangible assets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales, service, and commercialization\u003c\/td\u003e\n\u003ctd\u003e$4.8B\u003c\/td\u003e\n\u003ctd\u003eSelling, general and administrative expenses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRestructuring and cost actions\u003c\/td\u003e\n\u003ctd\u003e$0.1B\u003c\/td\u003e\n\u003ctd\u003eRestructuring and other charges\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eManufacturing and supply chain costs\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e$9.1B\u003c\/li\u003e\n\u003cli\u003e$23.9B\u003c\/li\u003e\n\u003cli\u003e$14.8B\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eR\u0026amp;D and AI development spending\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e$1.6B\u003c\/li\u003e\n\u003cli\u003e6.7%\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eAcquisition and integration costs\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e$0.1B\u003c\/li\u003e\n\u003cli\u003e$1.0B\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSales, service, and commercialization costs\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e$4.8B\u003c\/li\u003e\n\u003cli\u003e20.1%\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRestructuring and cost-action expenses\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e$0.1B\u003c\/li\u003e\n\u003cli\u003e0.4%\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eDanaher Corporation - Canvas Business Model: Revenue Streams\u003c\/h2\u003e\n\u003cp\u003eDanaher Corporation's revenue model is built on repeat sales tied to an installed base of instruments. In \u003cstrong\u003e2024\u003c\/strong\u003e, Danaher reported \u003cstrong\u003e$23.9 billion\u003c\/strong\u003e of sales, with \u003cstrong\u003e$7.6 billion\u003c\/strong\u003e in Biotechnology, \u003cstrong\u003e$5.9 billion\u003c\/strong\u003e in Life Sciences, and \u003cstrong\u003e$10.4 billion\u003c\/strong\u003e in Diagnostics.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue stream\u003c\/td\u003e\n\u003ctd\u003eDanaher business area\u003c\/td\u003e\n\u003ctd\u003e2024 reported sales\u003c\/td\u003e\n\u003ctd\u003ePublic disclosure status\u003c\/td\u003e\n\u003ctd\u003eRevenue pattern\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioprocessing consumables\u003c\/td\u003e\n\u003ctd\u003eBiotechnology\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.6 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNot separately disclosed from segment sales\u003c\/td\u003e\n\u003ctd\u003eRepeated purchases tied to biomanufacturing runs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics assays and reagents\u003c\/td\u003e\n\u003ctd\u003eDiagnostics\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.4 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNot separately disclosed from segment sales\u003c\/td\u003e\n\u003ctd\u003ePer-test consumption creates recurring demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstrument and analyzer sales\u003c\/td\u003e\n\u003ctd\u003eBiotechnology, Life Sciences, Diagnostics\u003c\/td\u003e\n\u003ctd\u003eIncluded in \u003cstrong\u003e$23.9 billion\u003c\/strong\u003e total sales\u003c\/td\u003e\n\u003ctd\u003eNot separately disclosed as a separate line item\u003c\/td\u003e\n\u003ctd\u003eInfrequent replacement and expansion sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService and support revenue\u003c\/td\u003e\n\u003ctd\u003eBiotechnology, Life Sciences, Diagnostics\u003c\/td\u003e\n\u003ctd\u003eIncluded in \u003cstrong\u003e$23.9 billion\u003c\/strong\u003e total sales\u003c\/td\u003e\n\u003ctd\u003eNot separately disclosed as a separate line item\u003c\/td\u003e\n\u003ctd\u003eContract, repair, validation, and technical support sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring high-margin consumables sales\u003c\/td\u003e\n\u003ctd\u003eBiotechnology and Diagnostics\u003c\/td\u003e\n\u003ctd\u003eAnchored by \u003cstrong\u003e$7.6 billion\u003c\/strong\u003e and \u003cstrong\u003e$10.4 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eNot separately disclosed as a single revenue line\u003c\/td\u003e\n\u003ctd\u003eRepeat purchase model with strong pricing power\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eBioprocessing consumables\u003c\/strong\u003e are the most direct repeat-sale stream inside Biotechnology. Danaher does not break out a separate consumables line in public reporting, so the best disclosed figure is the segment total of \u003cstrong\u003e$7.6 billion\u003c\/strong\u003e in 2024. That matters because every production run needs ongoing material input, which keeps revenue linked to customer throughput rather than one-time equipment purchases.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDiagnostics assays and reagents\u003c\/strong\u003e are the clearest per-test revenue stream. Danaher reported \u003cstrong\u003e$10.4 billion\u003c\/strong\u003e of Diagnostics sales in 2024, and the revenue logic is simple: each test consumes reagents or assay components. This gives the business a recurring base that is more stable than pure instrument replacement sales.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eInstrument and analyzer sales\u003c\/strong\u003e remain important because they create the installed base that later drives recurring purchases. Danaher does not disclose a separate 2024 dollar amount for instruments or analyzers, so those sales sit inside the \u003cstrong\u003e$23.9 billion\u003c\/strong\u003e company total. This stream is less frequent, but it often starts the long customer relationship that later produces consumables and service revenue.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eService and support revenue\u003c\/strong\u003e is embedded in the reported segments rather than shown as a standalone line. Public filings do not give a separate 2024 dollar amount for service, support, maintenance, or technical contracts, but these sales matter because they are tied to uptime, compliance, and installed equipment performance. That makes them recurring and less volatile than new equipment orders.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRecurring high-margin consumables sales\u003c\/strong\u003e are the main reason Danaher's revenue quality is strong. The company's reported 2024 sales profile shows two large repeat-purchase pools: \u003cstrong\u003e$7.6 billion\u003c\/strong\u003e in Biotechnology and \u003cstrong\u003e$10.4 billion\u003c\/strong\u003e in Diagnostics. These categories matter because customers keep buying them after the first instrument sale, which supports repeat revenue and usually better margins than hardware-only sales.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$23.9 billion\u003c\/strong\u003e total Danaher sales in 2024\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$10.4 billion\u003c\/strong\u003e Diagnostics sales in 2024\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$7.6 billion\u003c\/strong\u003e Biotechnology sales in 2024\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$5.9 billion\u003c\/strong\u003e Life Sciences sales in 2024\u003c\/li\u003e\n\u003cli\u003eService and support revenue not separately disclosed in public segment reporting\u003c\/li\u003e\n\u003cli\u003eConsumables, assays, and reagents are the main recurring revenue base\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":44601593397397,"sku":"dhr-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/dhr-business-model-canvas.png?v=1740165611","url":"https:\/\/dcf-analysis.com\/products\/dhr-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}